ArticleBMC neuroscience2009
Differential response of C57BL/6J mouse and DBA/2J mouse to optic nerve crush.
Article in BMC neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Meta-analysis of transcriptomic changes in optic nerve injury and neurodegenerative models reveals a fundamental response to injury throughout the central nervous system.Molecular vision · 2017Pooled it
- Analysis of retinal ganglion cell subtypes across six different inbred mouse strains.Molecular vision · 2026Article
- Optimizing retinal ganglion cell nuclear staining for automated cell counting.Experimental eye research · 2024Article
- Parvalbumin expression changes with retinal ganglion cell degeneration.Frontiers in neuroscience · 2023Article
- Quantitative proteomic analysis after neuroprotective MyD88 inhibition in the retinal degeneration 10 mouse.Journal of cellular and molecular medicine · 2021Article
- Commonalities of optic nerve injury and glaucoma-induced neurodegeneration: Insights from transcriptome-wide studies.Experimental eye research · 2021Review
- Chemokine CCL5 promotes robust optic nerve regeneration and mediates many of the effects of CNTF gene therapy.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- RNA sequencing profiling of the retina in C57BL/6J and DBA/2J mice: Enhancing the retinal microarray data sets from GeneNetwork.Molecular vision · 2019Article
- DDIT3 (CHOP) contributes to retinal ganglion cell somal loss but not axonal degeneration in DBA/2J mice.Cell death discovery · 2019Article
- AAV2-mediated GRP78 Transfer Alleviates Retinal Neuronal Injury by Downregulating ER Stress and Tau Oligomer Formation.Investigative ophthalmology & visual science · 2018Article
- The genetic dissection ofMolecular vision · 2018Article
- RBFOX3/NeuN is dispensable for visual function.PloS one · 2018Article
- JUN is important for ocular hypertension-induced retinal ganglion cell degeneration.Cell death & disease · 2017Article
- CNS repair and axon regeneration: Using genetic variation to determine mechanisms.Experimental neurology · 2017Review
- Gene expression changes in the retina following subretinal injection of human neural progenitor cells into a rodent model for retinal degeneration.Molecular vision · 2016Article
- Functional Role of γ-Crystallin N in the Auditory Hindbrain.PloS one · 2016Article
- Genetic Networks in Mouse Retinal Ganglion Cells.Frontiers in genetics · 2016Article
- Optic nerve crush induces spatial and temporal gene expression patterns in retina and optic nerve of BALB/cJ mice.Molecular neurodegeneration · 2014Article
- The RNA binding protein RBPMS is a selective marker of ganglion cells in the mammalian retina.The Journal of comparative neurology · 2014Article
- DBA/2J mice are susceptible to diabetic nephropathy and diabetic exacerbation of IOP elevation.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundRetinal ganglion cell (RGC) death is the final consequence of many blinding diseases, where there is considerable variation in the time course and severity of RGC loss. Indeed, this process appears to be influenced by a wide variety of genetic and environmental factors. In this study we explored the genetic basis for differences in ganglion cell death in two inbred strains of mice.
resultsWe found that RGCs are more susceptible to death following optic nerve crush in C57BL/6J mice (54% survival) than in DBA/2J mice (62% survival). Using the Illumina Mouse-6 microarray, we identified 1,580 genes with significant change in expression following optic nerve crush in these two strains of mice. Our analysis of the changes occurring after optic nerve crush demonstrated that the greatest amount of change (44% of the variance) was due to the injury itself. This included changes associated with ganglion cell death, reactive gliosis, and abortive regeneration. The second pattern of gene changes (23% of the variance) was primarily related to differences in gene expressions observed between the C57BL/6J and DBA/2J mouse strains. The remaining changes in gene expression represent interactions between the effects of optic nerve crush and the genetic background of the mouse. We extracted one genetic network from this dataset that appears to be related to tissue remodeling. One of the most intriguing sets of changes included members of the crystallin family of genes, which may represent a signature of pathways modulating the susceptibility of cells to death.
conclusionDifferential responses to optic nerve crush between two widely used strains of mice were used to define molecular networks associated with ganglion cell death and reactive gliosis. These results form the basis for our continuing interest in the modifiers of retinal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.